CRB invest in peptide manufacturing
23 May 2011 by Evoluted New Media
Cambridge Research Biochemicals – a research peptide and antibody manufacturer – is home to the first Overture Robotic Peptide Library Synthesiser.
Cambridge Research Biochemicals – a research peptide and antibody manufacturer – is home to the first Overture Robotic Peptide Library Synthesiser.
|
Overture at Cambridge Research Biochemicals |
Overture is one of the most powerful and sophisticated peptide synthesisers and will enable Cambridge Research Biochemicals (CRB) to offer its customers – researchers working in drug discovery and development – a much faster, more flexible service.
“The benefit that will be most apparent to our customers will be the ability of Overture’s cutting edge design to speed up the synthesis of peptides and tackle increasingly challenging molecules,” said Dr Laurent Caron, Peptide Core Technology Manager at CRB.
The peptide libraries produced by Overture can identify vitally important epitopes that cause peoples’ immune systems to react and which may be the key to developing new treatments.
Alison White, operations director at CRB said: “The Overture will be a significant asset in helping CRB to maintain its leading position as a high quality peptide manufacturer in a fast moving and evolving market.
CRB produce custom-made peptide and antibody tools, supplying researchers in pharmaceutical, life sciences and academic sectors. The provide laboratory scale reagents for proof of principle studies within early phase drug discovery and support biomarker programmes in clinical studies.
